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The in vitro effect of histamine and its antagonists, cimetidine and clemastine fumarate, on 
natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) activities of human 
lymphocytes was investigated. The histamine 1 (HI) antagonist, clemastine fumarate, and the 
histamine 2 (H2) antagonist, cimetidine, but not histamine alone, inhibited the NK and ADCC 
activities of lymphocytes when added directly to the mixture of effector and target cells in a 
5’Cr-release assay. This inhibition was proportional to the concentration of drugs added and was 
observed at various effector to target ratios against several targets. Hl and H2 antagonists also 
inhibited NK activities of T cells as well as Percoll-separated, NK-enriched effector cells. The 
inhibition was significantly reversed by histamine. In target binding assays, clemastine fumarate 
and cimetidine also decreased the target binding capacity of effector lymphocytes. Further, PBL 
precultured with histamine ( 1O-3-1O-4 M) for 24 hr showed a significant decrease in their NK 
and ADCC activities. In coculture experiments, PBL precultured with histamine suppressed the 
NK activity of normal autologous effector lymphocytes. PBL precultured with histamine showed 
an increased number of OKT8+ cells, as estimated using monoclonal antibodies. The suppression 
of cytotoxicity was not due to either direct toxicity, steric hindrance, crowding, or cell death, 
but by functionally viable suppressor cells. An immunoregulatory role for histamine in NK and 
ADCC reactions is proposed. 
INTRODUCTION 
We and our co-workers have previously demonstrated that unstimulated, cultured 
human peripheral blood lymphocytes (PBL)4 can develop suppressor cell activities 
against lymphocyte transformation, polyclonal B-cell activation, and natural killer 
(NK) and antibody-dependent cellular cytotoxicity (ADCC) reactions, as a possible 
consequence of an autologous mixed-lymphocyte culture reaction (l-3). We have 
also shown that serum-free culture supematants of unstimulated PBL contain soluble 
r Aided by National Institutes of Health Grant AI-16216 and a grant from the Children’s Leukemia 
Foundation of Michigan. 
2 To whom requests for reprints should he addressed: Department of Epidemiology, 2022 School of 
Public Health I, University of Michigan, Ann Arbor, Mich. 48 109. 
3 Recipient of NIH Research Career Development Award I-K04-CA-00896. 
’ Abbreviations used: ADCC, antibody-dependent cellular cytotoxicity; CEM, human T-lymphoblastoid 
cell line; E:T, effector to target ratio; Hl, histamine 1 receptor; H2, histamine 2 receptor; K562, human 
erythroleukemia cell line; NK, natural killer; PBL, peripheral blood lymphocytes depleted of adherent cells; 
SB, human B-leukemia cell line; TBC, target binding cells; Ty, T cells with Fc receptors for IgG. 
45 
0008-8749/83 $3.00 
Copyright C 1983 by Academic Press. Inc 
All rights of reproduction rn any form reserved 
46 NAIR AND SCHWARTZ 
suppressor factor(s) (SSF) that significantly exhibit suppressor activity toward mito- 
genesis and alloantigen stimulation in mixed-lymphocyte culture (4) and NK and 
ADCC reactions (5). Other studies on T-lymphocyte subpopulations have shown that 
T cells bearing Fc receptors for human IgG (Ty) mediate both NK and ADCC 
activities (6, 7) and exhibit suppressive effects on various lymphocyte reac- 
tions (8- 10). 
The role of histamine, a vasoactive amine, in immunoregulation has been extensively 
studied. In vitro investigations showed that histamine inhibits cell-mediated cytotox- 
icity, lymphocyte proliferative responses to mitogens and soluble antigens, lymphokine 
production, and the mixed-lymphocyte reaction ( 1 1 - 15). Our interest in immunoreg- 
ulation of natural and antibody-dependent cellular cytotoxicity of human lymphocytes 
led us to investigate the effect of histamine and histamine antagonists on NK and 
ADCC activities of human lymphocytes. The results indicate that lymphocytes pre- 
cultured with histamine demonstrated a significant decrease in their NK and ADCC 
activities and were able to suppress the NK activity of autologous effector cells in 
coculture experiments. An immunoregulatory role of histamine in cellular cytotoxic 
reactions is thus proposed. 
MATERIALS AND METHODS 
Drugs. The H 1 receptor blocker, clemastine fumarate (Tavist, Dorsey Labs, Lincoln, 
Nebr.), was used in a concentration range of 1 X lo-’ to 1 X 10d5 M, whereas the 
H2 receptor blocker, cimetidine (Smith-Kline and French Labs, Philadelphia, 
Pa.), was used in a concentration range of 1 X 10m4 to 2.5 X 10m2 ikf. Histamine 
(Sigma Chemical Co., St. Louis, MO.) was used in concentrations of 1 X 10e5 to 
1 x 1o-2 M. 
Experimental design. Drugs were added directly to the mixture of effector and 
target cells in a 4-hr 5’Cr-release assay. Controls containing either target and effector 
cells, or targets and drugs, were run concomitantly. In separate experiments, lym- 
phocytes were also precultured with histamine for 0 to 24 hr, washed, and tested for 
NK and ADCC activities or used in mixing experiments to measure their suppressive 
effects on autologous lymphocytes. 
Monoclonal antibodies. OKT3,OKT4, and OKT8 antibodies were purchased from 
the Ortho Pharmaceutical Corporation, Raritan, New Jersey and were used in a final 
dilution of 1: 100. These antibodies are complement (C) fixing and of the IgG isotype. 
Lymphocyte donors. Peripheral blood from adult healthy donors of both sexes was 
drawn into a plastic syringe containing heparin (20 U/ml). Donors were apprised of 
the study and consents were obtained consistent with the policies of The University 
of Michigan and the National Institutes of Health. 
Isolation of lymphocytes. PBL were isolated from heparinized venous blood using 
a modified method of Biiyum ( 16). Blood was diluted with an equal volume of normal 
saline and centrifuged at 400g for 30 min at 18°C. The mononuclear cell band was 
harvested, washed three times with saline, and resuspended in RPM1 1640 medium, 
containing 25 m&f HEPES buffer supplemented with 5% heat-inactivated fetal calf 
serum (FCS) (GIBCO, Grand Island, N.Y.), 80 pg/ml gentamicin (Shering Corp., 
Kenilworth, N.J.), and 300 pg fresh glutamine/ml (complete medium). 
Depletion of adherent cells. Mononuclear cells were depleted of adherent cells by 
passing through a G-10 column. PBL were suspended in RPM1 1640 with 10% FCS 
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and passaged through a 7-ml column of Sephadex G- 10 beads (Pharmacia Fine Chem- 
icals, Piscataway, N.J.), equilibrated in the same medium. After 45 min of incubation 
at 37°C nonadherent cells were washed through with one bed volume ofwarm (37°C) 
medium. The cell recovery was >70% of the total input, and macrophage contam- 
ination as indicated by nonspecific esterase staining was ~2%. 
Preparation of T cells. T cells were prepared as described elsewhere (17). Briefly, 
4 x lo6 PBL depleted of adherent cells were mixed with 0.25 ml of heat-inactivated 
FCS preabsorbed with sheep red blood cells (SRBC) and 1 ml of 1% packed volume, 
neuraminidase-treated (25 U/ml in a 5% SRBC suspension) SRBC. The mixture was 
incubated at 37°C for 5 min and centrifuged at 200s for 5 min followed by incubation 
at 4°C for 1 hr. The pellets were gently resuspended and T cells rosetted with SRBC 
were separated from non-T lymphocytes on a Ficoll-Hypaque (Pharmacia) density 
gradient by centrifugation at 48Og for 20 min at 20°C. SRBC attached to the isolated 
T lymphocytes (pellet) were lysed by hypotonic treatment with 1 ml of distilled water, 
followed by 1 ml of double-strength minimal essential medium (MEM, GIBCO). 
T cells were washed three times with RPM1 1640 and resuspended in complete 
medium and preincubated for 24 hr before use. 
PercoN fractionation of lymphocytes. The enrichment of NK effector cells using a 
discontinuous gradient of Percoll (Pharmacia) was carried out as described elsewhere 
(18). To prepare a discontinuous density gradient, Percoll solution was mixed at 
various concentrations with RPM1 1640 medium, and 2-ml aliquots (ranging from 
50.0 to 37.5% in 2.5% increments) were gently layered into 15 X 130-mm round- 
bottom glass test tubes. Adherent cell-depleted lymphocytes were layered on top of 
the gradient and centrifuged at 3008 for 45 min at 20°C. Six fractions, with the 
uppermost (37.5%) designated “0” and the lowermost (50.0%) designated “V,” were 
collected from the top with a Pasteur pipet and washed twice in RPM1 1640 medium. 
The least dense fraction banding at the 37.5% Percoll interface consistently showed 
the highest NK activity and was used routinely as a source of NK-enriched cells. 
Recovery of cells was 85% of that input, and viability always exceeded 95% by trypan 
blue dye exclusion. 
In vitro incubation of lymphocytes with histamine. Lymphocytes depleted of adherent 
cells, T cells, and Percoll-separated NK-enriched effector cells were suspended in 
complete medium at a concentration of 3 X lo6 cells/ml to which histamine was 
added. A duplicate set of cultures received RPM1 1640 medium instead of histamine 
as control. Cell cultures were incubated for 0 to 24 hr in a humidified environment 
of 5% CO2 in air at 37°C. Cells were washed twice and resuspended in complete 
medium. Cell viability was comparable with that of control cultures as determined 
by trypan blue dye exclusion and was not affected by histamine concentrations of 
< 1 X 1 O-* M. Treated and control cultures were tested for their ability to mediate 
NK and ADCC activities. 
Tumor target cells. The human erythroleukemia cell line, K562, and T-lympho- 
blastoid cell line, CEM, were used as targets for NK cells. For the ADCC assay, we 
chose as targets a human B-cell leukemia line (SB) because of resistance to NK activity 
in a 4-hr “Cr-release assay. 
Preparation of target cells. Passaged 48hr-old target cells were washed twice with 
complete medium. To 0.8 ml aliquots of complete medium containing 5 X IO6 tumor 
cells, 200 &i of 5’Cr as sodium chromate (New England Nuclear, Boston, Mass.) 
was added. The cells were incubated at 37°C for 1 hr in a humidified atmosphere 
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of 5% CO;! in air with intermittent shaking. Following incubation, the cells were 
washed three times with complete medium and resuspended to a concentration of 
2 X lo5 cells/ml. 
Assay fir NK activity. NK activity was determined in a direct 5’Cr-release assay 
as previously described (3, 5, 19,20). Briefly, varying concentrations of viable effector 
cells in complete medium were added to triplicate cultures of 5’Cr-labeled target cells 
in 0.2-ml volumes in V-bottom microtitration plates (Dynatech Labs, Alexandria, 
Va.). After centrifugation at 40g for 2 min, they were incubated at 37°C in a humidified 
atmosphere of 5% COz in air for 4 hr. Percentage cytotoxicity was calculated as 
% cytotoxicity = 
experimental release - spontaneous release 
total release - spontaneous release 
x 100, 
where spontaneous release represents counts released from control wells containing 
only 2 X lo4 target cells, and total release represents counts obtained in an aliquot 
of 2 X lo4 lysed target cells. 
Assay for ADCC. The ADCC activity of effector cells was determined by the original 
method of Perlmann and Perlmann (21) as modified by Handwerger and Koren (22). 
Briefly, 50 ~1 of varying concentrations of effector cells was added to 50 ~1 of complete 
medium containing 5’Cr-labeled SB target cells and 100 ~1 of a 2 X 10v4 dilution of 
rabbit anti-SB antisera previously found to yield maximal ADCC. Percentage ADCC 
activity was calculated as described above for NK activity with the following exceptions. 
Spontaneous release represents counts released in control wells containing effector 
cells, labeled SB target cells, and medium instead of anti-SB antibodies, and total 
release represents counts obtained in an aliquot of 1 X lo4 5’Cr-labeled SB target 
cells. Percentage inhibition of NK and ADCC activities by drugs was calculated as 
% cytotoxicity of control lymphocytes 
% inhibition = 
- % cytotoxicity of drug treated lymphocytes x loo 
% cytotoxicity of control lymphocytes 
Assayfor complement-dependent cytotoxicity. Lymphocytes (5 X 106) were suspended 
in serum-free RPM1 1640 medium to which monoclonal antibodies were added to 
yield a final titer of 1: 100 (previously found to be optimal). The cultures were incubated 
at room temperature for 30 min. They were then washed twice with serum-free 
medium and suspended in a 1:4 final dilution of rabbit complement. The mixtures 
were incubated for 1 hr at 37°C and washed twice with serum-free medium. The 
number of positive cells stained with trypan blue was counted, using a hemacytometer. 
Target binding assay. Target binding cell (TBC) assay was used as described by 
Haliotis et al. (23). In brief, lymphocytes precultured separately with either of the 
drugs, or without drugs, were washed twice and mixed with a fivefold excess of tumor 
cells centrifuged at 15Og for 5 min and incubated at 37°C for 5 min. Following 
incubation, lymphocyte-target mixtures were transferred to ice, the pellets were gently 
resuspended, and the number of lymphocytes binding to tumor targets was determined, 
using a hemacytometer. 
RESULTS 
Eflect of Histamine on NK and ADCC Activities of Lymphocytes 
In view of the finding that human lymphocytes have histamine receptors, and such 
lymphocytes exert various immunoregulatory functions in man ( 1 l- 14, 24-26), the 
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influence of histamine on NK and ADCC activities of lymphocyte subpopulations 
was studied. Data presented in Table 1 show that histamine added at different con- 
centrations ranging’from 1 X 10e2 to 1 X lop5 M to the reaction mixture of fresh 
effector and target cells and incubated for 4 hr showed no significant effect on NK 
and ADCC activities of either total PBL or isolated T cells. 
Efect of Histamine Antagonists on NK and ADCC Activities of Lymphocytes 
Table 2 shows a dose-response effect of histamine antagonists, clemastine and 
cimetidine, on NK and ADCC activities of lymphocytes. Clemastine, at concentrations 
of 22.5 X 10e5 M, and cimetidine, at concentrations of 25 X 10e2 M, significantly 
inhibited NK and ADCC activities. Cimetidine at concentrations <5 X 10e2 M con- 
sistently showed detectable suppression of NK and ADCC activities of lymphocytes, 
although the level of suppression was not significant. Therefore, a concentration of 
5 X 10e2 M which was not toxic to effector or target cells was used in subsequent 
experiments. The results suggest that histamine antagonists inhibit or block NK and 
ADCC reactions of lymphocytes. 
Table 3 shows the inhibition of NK activity of lymphocytes against K562 and 
CEM targets and ADCC activity against SB targets at different E:T cell ratios by 
histamine and its antagonists. It is evident that the inhibitory effect of drugs occurs 
even at higher E:T cell ratios. No significant inhibition was obtained with histamine 
at any E:T cell ratios. 
The effect of histamine and its antagonists on NK and ADCC activities of lymphocyte 
subpopulations is presented in Table 4. The results demonstrate that Hi and H2 
antagonists significantly inhibited NK and ADCC activities of both PBL and T cells. 
Histamine did not produce any significant effect on NK and ADCC activities of either 
PBL or T cells. 
TABLE 1 
Effect of Histamine on NK and ADCC Activitiesa 




PBL’ T cellsd 
ADCC’ NK ADCC 
0 50.0 f  3.4 36.1 + 5.2 46.2 3~ 2.6 34.3 f  2.5 
I x 10-S 46.2 f  5.8 38.2 + 1.3 39.2 + 6.2 31.8 f  2.8 
1 x 10-e 44.7 + 8.6 35.0 z!I 3.0 42.7 f  2.9 28.6 -t 3.2 
1 x 10-r 47.1 f  2.4 35.6 2 5.5 41.3 f  7.5 30.0 f  3.2 
1 x 1o-2 47.3 f  1.3 34.4 2 3.5 41.0 f  3.2 27.7 + 4.2 
’ Histamine was added directly to the mixture of effector and target cells in a 4-hr “Cr-release assay. 
Results are expressed as means f  SEM of triplicate determinations from a representative experiment and 
four separate experiments gave similar results. 
b Percentage cytotoxicity was calculated as described under Materials and Methods. 
’ PBL depleted of adherent cells as described under Materials and Methods. 
d T cells separated by resetting as described under Materials and Methods. 
’ NK activity was measured against the human erythroleukemia cell line, K562. 
I ADCC activity was measured against the human B-Iymphoblast cell Iine, SB, sensitized with anti-SB 
sera. 
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TABLE 2 
Dose-Response Effect of Antihistaminics on NK and ADCC Activities” 
Cytotoxicity (%) b 
Concentration 
Dw (M) NK’ ADCCd 
None - 70.2 + 2.4 50.8 r 2.4 
Clemastine fumarate 1 x 10-E 74.0 f  3.2 52.0 r 2.7 
1 x 10-7 72.0 f  2.1 49.2 z!z 4.2 
5 x 10-7 66.5 + 1.1 45.7 r 3.2 
5 x lo+ 63.5 f  8.4 48.7 k 4.2 
7.5 x lo+ 64.8 f  5.3 47.5 rt 2.2 
2.5 x lo-’ 38.4 k 2.3* 37.6 r 4.3* 
1 x 10-r 9.0 f  4.3** 10.7 + 11.8** 
Cimetidine 1 x lo-4 72.0 + 2.8 52.0 + 2.8 
5 x lo+ 50.9 + 4.8 46.3 + 4.3 
7.5 x lo+ 43.7 + 2.4 43.3 f  4.9 
5 x 10-s 26.2 -t 1.4; 20.8 f  3.9* 
2.5 x lO-2 10.2 + 2.8** 13.7 + 3.3** 
’ Drugs were added directly to the mixture of effector and target cells in a 4-hr assay at a 50: 1 ET ratio. 
b Percentage cytotoxicity was calculated as described under Materials and Methods. Results are expressed 
as means + SEM of four experiments. 
c NK activity was measured against the human erythroleukemia cell line, K562. 
d ADCC activity was measured against the human B-lymphoblast cell line, SB, sensitized with anti-SB 
sera. 
* P < 0.05. 
** P < 0.01. 
Data presented in Table 5 reveal the effect of drugs on Percoll-separated NK- 
enriched effector cells. Clemastine and cimetidine significantly inhibited NK activity 
of enriched effector cells while histamine did not manifest any significant effect on 
NK activity. 
To determine whether the addition of histamine reduces the inhibitory effect of 
antihistaminics, we added histamine together with antihistaminics to the test system 
in a 4-hr assay (Table 6). Addition of either clemastine and cimetidine alone to the 
reaction mixture significantly inhibited NK and ADCC activities of lymphocytes. 
The inhibitory effect of clemastine and cimetidine was markedly reduced by the 
simultaneous addition of histamine. The same concentration of histamine (1 X lop3 
M) used alone in the system did not produce any significant effect on either NK or 
ADCC activity of lymphocytes. 
Efect of Histamine Antagonists on Target Binding Cells 
To examine whether the suppression of cytotoxicity of lymphocytes by histamine 
antagonists is due to interference with a histamine receptor-associated target recognition 
structure rather than inhibition of the lytic mechanism, target binding assays were 
performed. The results of such studies are presented in Table 7. Clemastine (2.5 
X low5 M) and cimetidine (5 X 1 O-’ AI), at NK and ADCC inhibitory concentrations, 
significantly reduced the percentage of target binding lymphocytes (19 and 13%, 
respectively) compared to control lymphocytes (37%). Histamine at either 1 X 10m3 
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TABLE 5 








None - 28.0 + 2.8 
Clemastine 2.5 x 1o-5 14.0 * 1.0 50.0 
Cimetidine 5 x 1o-2 6.8 k 0.7 75.0 
Histamine I x 1om3 29.4 2 3.2 -5.0’ 
’ Drugs were added directly to the mixture of effector and target cells in a 4-hr “Cr-release assay at a 
10: 1 E:T ratio. 
’ Percentage cytotoxicity and percentage inhibition were calculated as described under Materials and 
Methods. Results are expressed as means + SEM oftriplicate determinations for a representative experiment, 
and four separate experiments gave similar results. 
‘Minus sign indicates enhancement. 
These results demonstrate that histamine antagonists affect the target recognition 
structure of lymphocytes rather than their lytic potential. 
Preculture of Lymphocytes with Histamine Suppresses NK and ADCC Activities 
Figure 1 reveals the results of a time-course study of PBL precultured with different 
concentrations of histamine for its effect on NK and ADCC activities. PBL precultured 
with histamine ( 1 X lo-* to 1 X 1O-4 M) for 0 to 12 hr were unaffected regarding 
their NK and ADCC activities. PBL precultured with histamine for 24 hr showed 
significant suppressive effects on their NK and ADCC functions. Maximal effect on 
NK (38% suppression) and ADCC (32% suppression) activities was obtained with a 
TABLE 6 



















- 47.8 f  4.2 - 35.0 -+ 3.3 - 
2.5 f  1O-5 14.2 f  1.8 70.2 20.4 f  2.1 41.7 
5.0 x 1o-2 18.0 f  1.9 62.3 13.5 I+ 1.6 61.4 
1.0 x 10-3 45.0 f  3.7 5.8 33.0 -+ 2.4 5.7 
2.5 x 1O-5 
1.0 x 10-j 29.2 + 3.1 38.9 30.2 k 4.0 13.7 
Cimetidine 
+ histamine 
5.0 x 10-Z 
1.0 x 10-j 32.4 f  3.0 32.2 27.6 2 3.6 21.1 
’ Drugs were added directly to the mixture of effector PBL depleted of adherent cells and target cells at 
a 50: 1 E:T ratio in a 4-hr ‘Q-release assay. Results are the mean +- SEM of triplicate determinations for 
one experiment, and four separate experiments gave similar results. 
b NK activity was measured against the human erythroleukemia cell line, K562. 
’ ADCC activity was measured against the human B-lymphoblastoid cell line, SB, sensitized with anti- 
SB sera. 
*Percentage cytotoxicity and percentage inhibition were calculated as described under Materials and 
Methods. 
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TABLE I 






Concentration Target binding cells 
W) (%o) 
- 31 zk 3.2 
2.5 x lo-5 19 + 1.8 
1 x lo-’ 40 +- 2.1 
5 x lo-2 13 + 1.0 
5 x 10-s 34 f  2.4 
1 x 10-r 35 rf: 3.6 
1 x lo-’ 33 1- 3.0 
Inhibition of target 








U Drugs were added to the mixture of lymphocytes depleted of adherent cells and K562 target cells and 
incubated as described under Materials and Methods. Lymphocytes bearing at least one surface-bound 
target cell were counted in a hemacytometer. Results are expressed as means f  SEM of three separate 
experiments. 
b Minus sign indicates enhancement. 
1 X 10d3 M histamine concentration. Table 8 shows the effects of preculture of PBL 
with histamine on NK and ADCC activities at different E:T cell ratios. Suppression 
of both NK and ADCC functions of PBL precultured with histamine was evident 
even at higher E:T cell ratios. Studies on the effects of histamine on lymphocyte 
subpopulations reveal that T lymphocytes and Percoll-enriched NK effector cells, 
when cultured with histamine, also show suppression of their NK activity at different 
E:T cell ratios (Table 9). 
Lymphocytes Preincubated with Histamine Suppress NK Activity of Autologous Normal 
Lymphocytes 
In coculture experiments to measure suppression, Percoll-separated NK-enriched 
lymphocytes precultured with histamine were added to a mixture of autologous effkctor 
cells and prelabeled target cells at different effector to inhibitor (E:I) ratios. Results 
are presented in Table 10. At E:I cell ratios of 1: 1 or less, lymphocytes precultured 
with histamine significantly suppressed the NK activity of autologous effector cells. 
Similar results were obtained when total peripheral blood mononuclear cells were 
precultured with histamine and tested for their suppressive effect on autologous effector 
cells in coculture experiments (data not presented). 
To rule out the possibility that crowding, steric hindrance, or cell death could cause 
suppression of NK activity, we examined the effect of (1) normal human RBC, (2) 
PBL preincubated with histamine and then heat killed (56°C for 30 min), and (3) 
heat-killed effector cells on the NK activity of autologous effector cells. The results 
demonstrate that the addition of any of these cells as inhibitors to the reaction mixture 
at E:I cell ratios of 1: 1 or less did not produce any significant suppression of NK 
activity by autologous effector cells (data not presented). This suggests that the 
suppression of NK activity by histamine-induced suppressor cells observed in the 
present experiments was not caused by crowding, steric hindrance, or cell death, but 
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FIG. 1. Time course study of NK and ADCC activities of PBL precultured with histamine. PBL depleted 
of adherent cells were precultured alone or with histamine (1 X IO-* to 1 X 10e4 M) for 0 to 24 hr, washed 
twice, and tested for NK and ADCC activities. Results are expressed as mean percentages of suppression 
of cytotoxicity f  SEM of four separate experiments with triplicate determinations for each experiment at 
a 50~1 E:T cell ratio. 
PBL Precultured with Histamine Show Increased Numbers of OKTS’ Cells 
As OKT8+ lymphocytes are capable of suppressing various immune reactions (27, 
28) experiments were undertaken to determine if lymphocytes precultured with his- 
tamine express increased number of OKT8+ cells. PBL depleted of adherent cells 
precultured with histamine (1 X 1O-3 M) for 24 hr were washed and examined for 
OKT3+, OKT4+, and OKT8+ subpopulations, using monoclonal antibodies in a 
complement-dependent cytotoxicity assay (Table 11). PBL precultured with histamine 
showed no changes in either OKT3+ or OKT4+ subpopuiations compared to control 
cultures. However, an 11% increase in OKTV cells from 2 1% to 32% was observed 
after preculture with histamine. This suggests that histamine modulates NK and 
ADCC activities of lymphocytes by activating OKT8+ suppressor cells. 
DISCUSSION 
NK and ADCC cells have been gaining attention because of their proposed role 
in defense against tumors and in the regulation of various lymphoid cell reactions 
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TABLE 8 
NK and ADCC Activities of PBL Precultured with Histamine at Various Effector to Target Cell Ratios’ 
Cytotoxicity (%)b 
Histamine NK’ ADCCd 
concentration 
ef) E:T = 5O:l’ E:T = 2o:l E:T = 1O:l E:T = 5O:l E:T = 2o:l E:T = 1O:l 
0 40.0 f  4.4 32.6 f  3.3 20.1 f  1.9 42.4 +: 4.4 27.9 + 2.7 16.1 + 1.8 
1 x 10-s 28.1 f  2.4 19.6 ? 1.8 8.5 + 0.6 28.0 + 2.8 18.2 + 1.6 4.7 + 0.4 
(29.7)l (39.8) (57.7) (33.9) (34.7) (70.8) 
’ PBL depleted of adherent cells were cultured with or without histamine (1 X lo-’ M) for 24 hr, washed, 
and tested for NK and ADCC activities. 
b Percentage cytotoxicity was calculated as under Materials and Methods. 
c NK activity was measured against the human erythroleukemia cell line, K562. 
d ADCC activity was measured against the human B-lymphoblast cell line, SB, sensitized with anti-SB 
sera. 
e Effector to target cell ratio. 
’ Numbers in parentheses indicate the percentage inhibition. Results are expressed as mean f  SEM of 
four experiments. 
(29-3 1). Studies from our laboratory and by others have shown that NK and ADCC 
activities are also subject to regulation by suppressor cells or their soluble products 
(3, 5, 19, 20, 3 l-34). Earlier investigations have shown that human T cells with Fc 
TABLE 9 
NK Activity of T Cells and NK-Enriched Lymphocytes Precultured with Histamine” 
Cytotoxicity (W)b 
Histamine NK-enriched cells’ T cellsd 
concentration 
0-f) E:T = 2O:l’ E:T = lo:1 E:T = 5:1 E:T = 50:1 E:T = 20:1 E:T = 1O:l 
0 73.2 f  8.6 68.1 k 7.9 54.6 + 6.7 69.0 k 5.5 62.0 k 9.2 37.1 L!z 4.5 
1 x lo-s 77.2 + 7.3 70.9 + 6.7 57.4 +- 5.3 64.8 + 4.3 57.2 + 5.1 39.6 f  3.9 
(-5.4)’ (-4.1) (-5.1) (6.0) (7.7) (-6.7) 
1 x lo-4 76.4 + 6.6 75.8 + 7.8 58.4 z!z 4.8 64.3 + 6.6 54.7 -c 5.4 27.4 f  3.2 
(-4.3) (-11.3) (-6.9) (6.8) (11.7) (26.1) 
1 x lo-3 60.1 f  5.6 50.5 f  4.8 30.3 f  4.3 52.8 + 2.8 23.0 f  3.3 5.9 f  3.8 
(17.8) (25.8) (44.5) (23.4) (62.9) (84.0) 
a T lymphocytes and Percoll-separated NK-emiched effector lymphocytes were precultured with histamine 
for 24 hr, washed, and tested for NK activity. Values are the means + SEM of triplicate determinations 
for a representative experiment. Three separate experiments gave similar results. 
b Percentage cytotoxicity was measured against the erytholeukemia cell line, K562, as described under 
Materials and Methods. 
c NK-enriched lymphocytes were separated on a Percoll density gradient as described under Materials 
and Methods. 
d T cells were separated by resetting as described under Materials and Methods. 
’ Effector to target cell ratio. 
’ Numbers in parentheses are percentage inhibition and a minus sign indicates enhancement. 
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TABLE 10 





2 x lo5 
2 x 10s 
2 x 105 
2 x 105 
2 x 105 
- 
I x lo6 
8 x IO5 
6 x I05 
4 x 105 






24.7 f  2.4 
19.0 + 1.2 
17.4 f  2.6 
18.2 zk 1.5 
14.5 + 2.8 
E:I 
ratio d 
Effector cell cytotoxicity 
(%) 
Observed ’ Predicted’ 
Suppression 
es 
- 35.2 + 4.2 - - 
I:5 33.2 f  1.2 59.9 44.5 
I:4 29.3 f  2.9 54.2 45.9 
1:3 28.7 f  1.8 52.6 45.4 
1:2 32.8 + 2.4 53.4 30.4 
l:l 36.4 ?I 3.2 49.7 26.7 
n Percoll-separated NK-enriched lymphocytes precultumd in medium alone for 24 hr were used as effecters 
at an E:T ratio of 1O:l. 
b Autologous Percoll-enriched lymphocytes were precultured with histamine ( 1 Om3 M) for 24 hr, washed, 
and used as inhibitor cells at different ratios. 
’ Percentage cytotoxicity was measured as described under Materials and Methods. 
d Effector to inhibitor cell ratio. 
e Predicted cytotoxicity equals sum of the percentage of the cytotoxicities of the effector and inhibitor 
cells measured separately. 
’ Percentage inhibition = (predicted % cytotoxicity - observed % cytotoxicity/predicted % cytotoxicity) 
X 100. The results are expressed as the mean + SEM of a representative experiment and three other 
experiments produced similar results. 
receptors for IgG (Ty cells) are involved in NK and ADCC mechanisms (6, IO), as 
well as in the regulation of other immunologic reactions (8-10). 
Recently histamine, a vasoactive amine, has been shown to play a role in im- 
munoregulation (11, 13,24,25,35,36). Rocklin et al. (26) reported that T lymphocytes 
exposed to histamine in vitro elaborate a soluble factor which suppresses the production 
of migration inhibition factor and proliferation by sensitized lymphocytes. Szewcznk 
et al. (37) showed that in vivo injection of histamine with trinitrophenylated bovine 
a-globulin into mice induced the formation of autoanti-idiotypic antibodies, which 
regulate the immune response to trinitrophenylated bovine a-globulin. Beer et al. 
( 12) recently showed that PBL precultured in the presence of histamine ( lop4 to 1 Op3 
M) for 24 hr could function as suppressor cells in a coculture experiment. The Ty 
TABLE 11 
Effect of Histamine on T-Cell Subpopulations” 
Histamine 
concentration 
of) OKT3 (%) OKT4 (W) OKT8 (%) 
0 62.5 f  3.5 22.5 f  2.1 21.0 +- 2.8 
1 x 10-3 57.3 f  7.7 19.5 lr 0.7 32.1 + 2.7 
a PBL depleted of adherent cells were cultured alone or with 1 X 10m3 M histamine for 24 hr, washed, 
and tested for lymphocyte subpopulations, using monoclonal antibodies by a complementdependent cytotoxic 
assay. The number of positive cells stained with trypan blue were counted, using a hemacytometer. Values 
represent the mean + SEM of three experiments. 
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subpopulation, which mediates potent NK and ADCC reactions (6, lo), has been 
shown to possess histamine receptors (26). It was of interest, therefore, to examine 
whether histamine receptor-bearing lymphocytes are involved in the regulation of 
NK and ADCC activities. We report here a previously unrecognized immunosup- 
pressive effect of histamine on NK and ADCC activities of normal lymphocytes, i.e., 
lymphocytes precultured with histamine showed significant suppression of NK and 
ADCC activities, and were able to suppress the NK activity of autologous effector 
cells in coculture experiments. An immunoregulatory role of histamine for NK and 
ADCC reactions is thus proposed. 
We further demonstrate that the histamine antagonists, clemastine fumarate and 
cimetidine, when added directly to the reaction mixture of effector and target cells, 
block NK and ADCC activities in a dose-dependent fashion at different E:T cell 
ratios. This blocking effect was evident against Percoll-separated NK-enriched effector 
cells and T lymphocytes. Antihistamine-induced inhibition of cytotoxicity is reversed 
by the addition of histamine, which at the same dose did not affect NK or ADCC 
activities when added directly to the reaction mixture. This is consistent with the 
findings of others (38-42) who demonstrated the blocking effect of NK and ADCC 
activities by histamine antagonists. This suggests that histamine receptors are involved 
in these cytotoxic mechanisms and that blocking of such receptors impedes the cy- 
totoxic potential of lymphocytes. In TBC studies, the histamine antagonists, at NK 
or ADCC inhibitory doses, also reduced the number of target binding lymphocytes. 
This demonstrates that histamine antagonists interfere with a histamine receptor- 
associated target in target-effector interactions. 
Suppression is operationally defined herein as the inhibition of cytotoxicity of 
effector lymphocytes after addition of drugs directly into the mixture of effector and 
target cells, or after preculturing lymphocytes with drugs. The decrease of cytotoxicity 
is not due to direct cytotoxicity of effector cells, since lymphocytes treated with either 
clemastine or cimetidine showed normal spontaneous “Cr release, and the viability 
was comparable with that of untreated control cultures as measured by trypan blue 
dye exclusion test (data not presented). Lymphocytes precultured with histamine also 
showed comparable viability and normal spontaneous release of 5’Cr with that of 
untreated lymphocytes (data not presented). 
The natural history of effector cells involved in NK or ADCC mechanisms is still 
not clearly understood. In the human system, evidence indicates that at least some 
of the NK cells may belong to the T-lymphocyte lineage (43-45). The blocking of 
T-cell-mediated NK activities by histamine antagonists and the induction of suppressor 
cell activity by preculturing T cells with histamine may support a T-cell lineage of 
some NK effector cells. Our study further reveals that histamine exerts a suppressive 
effect on Percoll-separated NK-enriched effector cells, and histamine-induced sup 
pressor cells were able to inhibit the NK activity of normal cells in autologous coculture 
experiments. 
It has been shown that suppressor T cells are recognized by OKT8 monoclonal 
antibodies and that such T cells are known to suppress several immunologic functions 
(27,28). We have examined the number of OKT8+ T cells present in the T-lymphocyte 
population precultured with histamine and have demonstrated an increase in the 
number of OKT8+ cells. The number of OKT3+ and OKT4+ subpopulations, however, 
remained unchanged suggesting that OKT8+ cells are either recruited from precursors 
or from OKT3+ or OKT4+ subpopulations by histamine. It is thus possible that 
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histamine-treated PBL may exhibit a complex phenotype with coexpression of OKT3, 
OKT4, and OKT8 markers. These questions are presently under investigation in our 
laboratory. This supports the premise that histamine activates OKT8+ cells to express 
suppressor effects on NK and ADCC reactions. 
The present report demonstrates that lymphocytes with histamine receptors are 
involved in NK and ADCC reactions and can be activated upon culturing with 
histamine to express suppressor functions. This dual role of histamine receptor-bearing 
lymphocytes in the mediation and regulation of NK and ADCC mechanisms merits 
further study. Examination of any deficiencies of NK and ADCC activities in certain 
allergic, inflammatory or immunologically mediated diseases associated with vasoactive 
amines such as histamine and its antagonists, has important clinical significance. 
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